NCT05991284View on ClinicalTrials.gov

Sacubitril-Valsartan in Heart Failure with Preserved Ejection Fraction and Secondary Mitral Valve Regurgitation

PHASE4RecruitingINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

February 29, 2024

Primary Completion Date

September 1, 2026

Study Completion Date

December 1, 2026

Conditions
Heart Failure with Preserved Ejection FractionFunctional Mitral Regurgitation
Interventions
DRUG

Sacubitril-valsartan

sacubitril-valsartan (target dose 97/103 mg twice daily)

DRUG

Standard of care

including SGLT-2 inhibitor and MRA

Trial Locations (1)

3600

RECRUITING

Ziekenhuis Oost-Limburg, Genk

All Listed Sponsors
collaborator

Jessa Hospital

OTHER

lead

Ziekenhuis Oost-Limburg

OTHER